Berita/Reuters/Cingulate Submits New Drug Application To FDA For Lead Adhd Asset CTx-1301Cingulate Submits New Drug Application To FDA For Lead Adhd Asset CTx-1301RefinitivBacaan kurang dari 1 minitCINGCingulate Inc CING:CINGULATE SUBMITS NEW DRUG APPLICATION TO FDA FOR LEAD ADHD ASSET CTX-1301ReutersSaham AS© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.htmlPaparkan lebih lanjutLog masuk atau cipta satu akaun percuma selamanya untuk membaca berita iniJom pergi
